UK regulator approves drug that could extend lives of breast cancer patients National Institute for Health and Care Excellence gives NHS go-ahead to prescribe eribulin after new evidence shows drug may have ‘substantial’ benefits
Women with later-stage breast cancer may gain up to three months of extra life after health regulators gave the NHS the green light to prescribe the first new drug to treat the disease in almost a decade.
About 1,500 women a year in England who have locally advanced breast cancer, or whose disease has spread despite two rounds of chemotherapy, will be eligible to receive the life-extending drug. On average, they usually only have two years to live after they have been diagnosed. Continue reading... The Guardian
No comments:
Post a Comment